FAQ on NanoViricides' Phase II Mpox Trial Approval in DRC

What is NV-387 and what is its purpose?

NV-387 is a broad-spectrum antiviral drug developed by NanoViricides, Inc. designed to target multiple viruses, including Mpox (hMPXV), influenza, RSV, coronaviruses, and orthopoxviruses, with the aim of treating viral diseases that evade existing drugs.

Why is the Phase II clinical trial for NV-387 significant?

The Phase II clinical trial approval signifies progress in developing a potential breakthrough treatment for viral infections with limited or no current treatment options, particularly Mpox, in the Democratic Republic of Congo.

How does NV-387 work?

NV-387 is a host-mimetic antiviral that has shown strong preclinical results across multiple viruses, utilizing NanoViricides’ proprietary nanoviricide technology to combat viral infections effectively.

Who is conducting the Phase II clinical trial of NV-387?

NanoViricides, Inc. is conducting the trial, following approval from the Democratic Republic of Congo’s National Ethics Committee for Health, and is finalizing its Clinical Trial Application for submission to the Ministry of Public Health.

Where is the Phase II clinical trial for NV-387 taking place?

The trial is planned to take place in the Democratic Republic of Congo, following the approval from its National Ethics Committee for Health.

What are the potential implications of NV-387’s success?

Success in the clinical trials could lead to NV-387 becoming a groundbreaking treatment for a wide range of viral diseases, including Mpox, COVID-19, influenza, and other respiratory viral infections, addressing a significant unmet medical need.

How can I find more information about NanoViricides and NV-387?

For more information about NanoViricides and its drug candidates, including NV-387, visit their official website at www.NanoViricides.com or view the latest updates at https://ibn.fm/NNVC.

What other drug candidates is NanoViricides developing?

Aside from NV-387, NanoViricides is developing NV-HHV-1 for the treatment of Shingles and NV-CoV-2 and NV-CoV-2-R for COVID-19, showcasing its broad focus on antiviral therapies.